Fenwick & West represented Pharmakon Advisors in the transaction. Novocure (NASDAQ: NVCR) announced today that it has entered into a new five-year up to $400 million...
You must be a Standard 1 Year member to access this content.
Walder Wyss team advised the funds managed by Pharmakon Advisors LP, as leading investor. Novocure (NASDAQ: NVCR) has entered into a new five-year up to $400 million...
You must be a Standard 1 Year member to access this content.
Walder Wyss team advised the funds managed by Pharmakon Advisors, LP. Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a global pharmaceutical company primarily focused on investigating experimental oral...
You must be a Standard 1 Year member to access this content.
Akin advised Pharmakon Advisors on the deal. Pharmakon Advisors, LP, a leading investor in non-dilutive debt for the life sciences industry, announced its $450 million financing commitment...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised ImmunoGen, while Walder Wyss advised the funds managed by Pharmakon Advisors. ImmunoGen, Inc. (Nasdaq: IMGN) announced it has entered into a term loan...
You must be a Standard 1 Year member to access this content.
Fenwick advised Pharmakon on the deal while Akin Gump advised Pharmakon Advisors. Pharmakon, an investor in non-dilutive debt for the life sciences industry and the investment...
You must be a Standard 1 Year member to access this content.
Covington advised Insmed Incorporated on the deal while Fenwick represented Pharmakon. Walder Wyss advised the funds managed by Pharmakon Advisors, LP, BioPharma Credit and OrbiMed. Akin...
You must be a Standard 1 Year member to access this content.
